HELP
Cybin Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · CA
$12.22
+3.82%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | (44.7M) | 472.3K | — | 251.0K |
| Cost of Revenue | 30.2K | 119.2K | 472.3K | — | 251.0K |
| Gross Profit | (30.2K) | (44.8M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 109.0M | 86.0M | 54.9M | 32.4M | 25.5M |
| SG&A Expense | 68.1M | 56.0M | 88.2M | 46.5M | 26.0M |
| General & Admin Expense | 44.1M | 49.6M | 85.0M | 27.9M | 25.1M |
| Selling & Marketing Expense | 6.2M | 6.4M | 3.3M | 18.6M | 881.0K |
| Other Expenses | — | (45.2M) | — | — | — |
| Total Operating Expenses | 177.1M | 96.9M | 143.1M | 78.8M | 51.5M |
| Cost and Expenses | 177.2M | 97.0M | 143.6M | 78.8M | 51.8M |
| Operating Income (EBIT) | (177.2M) | (141.7M) | (143.1M) | (78.8M) | (51.5M) |
| Non-Operating | |||||
| Interest Income | 5.8M | 5.1M | 8.3M | 619.0K | 603.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 5.8M | 5.1M | 8.3M | 619.0K | 603.0K |
| Other Non-Op Income/Expense | (6.1M) | 84.0M | 29.5M | 756.0K | 3.8M |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (183.3M) | (57.7M) | (113.6M) | (78.1M) | (47.7M) |
| Income Tax Expense | — | 89.4M | (472.3K) | — | (251.0K) |
| Bottom Line | |||||
| Net Income | (183.3M) | (147.1M) | (113.1M) | (78.1M) | (47.5M) |
| Earnings from Cont. Ops | (183.3M) | (147.1M) | (113.1M) | (78.1M) | (47.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (183.3M) | (147.1M) | (113.1M) | (78.1M) | (47.5M) |
| Per Share | |||||
| Basic EPS | ($5.51) | ($4.23) | ($5.59) | ($3.91) | ($9.73) |
| Diluted EPS | ($5.51) | ($4.23) | ($5.59) | ($9.41) | ($9.74) |
| Revenue Per Share | $0.00 | ($1.28) | $0.02 | $0.00 | $0.05 |
| Shares | |||||
| Basic Shares Outstanding | 52.3M | 34.8M | 20.2M | 20.0M | 4.9M |
| Diluted Shares Outstanding | 52.3M | 34.8M | 20.2M | 20.0M | 4.9M |
| Profitability Metrics | |||||
| EBITDA | (177.0M) | (141.6M) | (142.9M) | (78.4M) | (51.3M) |
| D&A | 123.6K | 120.0K | 211.0K | 424.0K | 251.0K |
| EBIT | (177.2M) | (141.7M) | (143.1M) | (78.8M) | (51.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026